Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Ju-Hee, Ryoo, Na-Young, Shin, Dong Wun, Trojanowski, John Q, Shaw, Leslie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Physiological Society and The Korean Society of Pharmacology 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296032/
https://www.ncbi.nlm.nih.gov/pubmed/25598657
http://dx.doi.org/10.4196/kjpp.2014.18.6.447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296032/
https://www.ncbi.nlm.nih.gov/pubmed/25598657
http://dx.doi.org/10.4196/kjpp.2014.18.6.447

Ejemplares similares